dazukibart

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
dazukibart

GtoPdb Ligand ID: 14524

Synonyms: PF-06823859 | PF06823859

Compound class: Antibody

Comment: Dazukibart (PF-06823859) is a humanized monoclonal antibody that selectively neutralises interferon-beta (IFN-β) and blocks signalling via interferon receptors (IFNAR) [1]. Peptide sequences for the heavy and light chains of dazukibart are claimed as components of antibody CTI-AF1 in Pfizer's patent US10829553 [2].

References
1. Fiorentino D, Mangold AR, Werth VP, Christopher-Stine L, Femia A, Chu M, Musiek ACM, Sluzevich JC, Graham LV, Fernandez AP et al.. (2025) Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet, 405 (10473): 137-146. [PMID:39798982]
2. Gulla Sv, Huard C, Buhlmann JE, Almagro JC, Kodangattil SR, Greenberg SA, LaVallie ER, Bennett EM, Hall JP et al.. (2020) Interferon beta antibodies and uses thereof. Patent number: US10829553B2. Assignee: Pfizer Corp SRL, Brigham and Womens Hospital Inc. Priority date: 28/04/2017. Publication date: 10/11/2020.
3. Neelakantan S, Oemar B, Johnson K, Rath N, Salganik M, Berman G, Pelletier K, Cox L, Page K, Messing D et al.. (2021) Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study. Clin Pharmacol Drug Dev, 10 (3): 307-316. [PMID:33352008]

References

1. Fiorentino D, Mangold AR, Werth VP, Christopher-Stine L, Femia A, Chu M, Musiek ACM, Sluzevich JC, Graham LV, Fernandez AP et al.. (2025)
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet, 405 (10473): 137-146. [PMID:39798982]

2. Gulla Sv, Huard C, Buhlmann JE, Almagro JC, Kodangattil SR, Greenberg SA, LaVallie ER, Bennett EM, Hall JP et al.. (2020)
Interferon beta antibodies and uses thereof.
Patent number: US10829553B2. Assignee: Pfizer Corp SRL, Brigham and Womens Hospital Inc. Priority date: 28/04/2017. Publication date: 10/11/2020.

3. Neelakantan S, Oemar B, Johnson K, Rath N, Salganik M, Berman G, Pelletier K, Cox L, Page K, Messing D et al.. (2021)
Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study.
Clin Pharmacol Drug Dev, 10 (3): 307-316. [PMID:33352008]